
|Articles|April 15, 2006
More study needed before combination therapies for AMD accepted
Baltimore?Photodynamic therapy (PDT) has been the mainstay of treatment for choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) until recently when combination therapies (PDT and anti-vascular endothelial growth factor [VEGF]) agents started to be explored.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
3
Eye exams could enable earlier detection of systemic disease
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























